Merus Market Share Analysis for July 2026

Effective as of February 3, 2023. This “Privacy Statement” describes the privacy practices of Merus N.V. and our subsidiary Merus US, Inc. (collectively, “Company”, “we”, “us”, or “our”) relating to…

Health > Biotechnology and Pharmaceuticals

Domainmerus.nl

Year Founded2003

Employees201 - 500

Annual Revenue$50M - $75M

Merus

Merus (including company regionals)

merus.nl

See more website traffic and engagement information

Merus Revenue up to July 2026 is 50M - 75M

revenue generated by Merus top domains

Merus top domains revenue over 3 years

Revenue for Merus top domains

merus.nl50M - 75M

See more with Sales Intelligence

Total visits to Merus's top domains

Understand Merus market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

merus.nl8.8K

See more with Sales Intelligence

Avg. visit duration in Merus's top domains

Analyze Merus engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

merus.nl00:00:13

See more with Sales Intelligence

Avg. pageviews on Merus's top domains

See how Merus keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

merus.nl1.80

See more with Sales Intelligence

Merus top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by Merus

These are the website technologies, by industry, used by Merus top domains

Widget (5)

Twemoji

Marketing (3)

Google Marketing Platform

Advertising (2)

DoubleClick

Audio Video Media (2)

YouTube

More Technologies

8

See all

News & Signals from Merus

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsMerus B.V is developing subcutaneous formulation of petosemtamab on Nov 17th '25.November 17, 2025 SDBN news, PR newswire, syndication comments off on Merus and halozyme enter global collaboration and license agreement to develop subcutaneous formulation of petosemtamab.

NewsGenmab is planning to acquire Merus B.V for $8B.Genmab has agreed to acquire Netherlands-based biotech Merus for approximately $8 billion, giving it rights to late-stage breakthrough cancer therapy petosemtamab.

NewsMerus B.V attends event BofA Securities 2025 Health Care Conference.Merus to present at the 2025 Wells Fargo Healthcare Conference.